| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
FLT3-IN-2 targets FLT3 with an IC50 of less than 1 μM. By inhibiting FLT3, it blocks the downstream signaling pathways that promote the proliferation and survival of hematopoietic cells, making it a potential therapeutic target for acute myeloid leukemia (AML) and other hematological malignancies.
|
|---|---|
| ln Vitro |
In vitro, FLT3-IN-2 demonstrates potent inhibition of FLT3 kinase activity with an IC50 of less than 1 μM. Its activity is confirmed in cell-based assays where it inhibits the proliferation of FLT3-dependent cell lines.
|
| ln Vivo |
In vivo, FLT3-IN-2 supports the development of targeted therapies and advances research in cancer biology. As a FLT3 inhibitor, it has potential for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.
|
| Enzyme Assay |
The in vitro FLT3 kinase assay involves incubating the enzyme with a peptide substrate and ATP in the presence of varying concentrations of FLT3-IN-2. The amount of phosphorylated substrate is measured using a luminescent or fluorescent detection system, and the IC50 is calculated from the dose-response curve.
|
| Cell Assay |
In vitro cell-based assays for FLT3-IN-2 utilize FLT3-dependent cell lines, such as MV4-11 or MOLM-13. Cells are treated with the compound, and cell viability is assessed by MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal experiments for FLT3-IN-2 would typically involve xenograft models using FLT3-dependent human leukemia cells. The compound would be administered orally or intraperitoneally, and tumor growth would be monitored.
|
| ADME/Pharmacokinetics |
FLT3-IN-2 has a molecular weight of 416.83 g/mol and is soluble in DMSO at 30 mg/mL. It is typically stored as a powder at -20°C. For in vivo studies, it can be formulated in suitable vehicles.
|
| Toxicity/Toxicokinetics |
Toxicological data for FLT3-IN-2 are limited, as it is a research compound. It is not intended for human use. Standard safety precautions for handling chemical reagents should be followed.
|
| References | |
| Additional Infomation |
FLT3-IN-2 is a research compound with no clinical approval. It is a valuable tool for studying FLT3 biology and the role of FLT3 in hematological malignancies. It is used in drug discovery programs to explore the therapeutic potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.
|
| Molecular Formula |
C₂₁H₁₆CLF₃N₄
|
|---|---|
| Molecular Weight |
416.83 Synonym
|
| Exact Mass |
416.101
|
| CAS # |
923562-23-6
|
| PubChem CID |
59593294
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.658
|
| LogP |
5.86
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
527
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1CNC2=NC=C(C=C2)CC3=CNC4=C3C=C(C=N4)Cl)C(F)(F)F
|
| InChi Key |
MFXPJGJSKHZZGC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H16ClF3N4/c22-17-8-18-15(11-28-20(18)29-12-17)7-14-3-6-19(27-10-14)26-9-13-1-4-16(5-2-13)21(23,24)25/h1-6,8,10-12H,7,9H2,(H,26,27)(H,28,29)
|
| Chemical Name |
5-[(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)methyl]-N-[[4-(trifluoromethyl)phenyl]methyl]pyridin-2-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~71.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
